Please enable JavaScript to continue using this application.

Compare $CHRS vs $NBP | Chartloom

Compare

$CHRS vs $NBP

Coherus Oncology Inc · NovaBridge Biosciences

CHRS

Coherus Oncology Inc

NBP

NovaBridge Biosciences

Compare $CHRS vs $NBP

Comparing Coherus Oncology Inc and NovaBridge Biosciences

CHRSCoherus Oncology Inc

NBPNovaBridge Biosciences

CHRSCoherus Oncology Inc

Market cap

$165M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

2.04x

Rev growth (TTM)

-64.3%

YTD performance

-21.9%

52W performance

-39.2%

FCF yield

-112.7%

NBPNovaBridge Biosciences

Market cap

$161M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-67.3%

52W performance

-72.5%

FCF yield

-33.9%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CHRS

NBP

Detailed metrics comparison

CHRS

Coherus Oncology Inc

NBP

NovaBridge Biosciences

Market Cap

CHRS$165M

NBP$161M

Enterprise Value

CHRS$134M

NBP$-30M

Price

CHRS$1.07

NBP$1.40

P/E Ratio

CHRSN/A

NBPN/A

P/S Ratio

CHRS3.24x

NBP3.29x

EV/Sales

CHRS2.63x

NBP0.00x

EV/EBITDA

CHRS2.57x

NBP0.00x

P/B Ratio

CHRS2.95x

NBP0.77x

P/FCF Ratio

CHRSN/A

NBPN/A

EV/FCF

CHRS-0.72x

NBP0.55x

PEG Ratio

CHRSN/A

NBPN/A

Forward P/E (NTM)

CHRSN/A

NBPN/A

Forward P/S (NTM)

CHRS2.04x

NBPN/A

Revenue (TTM)

CHRS$51M

NBP$0

Revenue Growth (YoY)

CHRS-64.3%

NBPN/A

Forward Rev Growth

CHRS67.8%

NBP419.8%

Gross Margin (TTM)

CHRS68.9%

NBP100.0%

Operating Margin (TTM)

CHRS0.0%

NBP0.0%

EBITDA Margin (TTM)

CHRS-288.0%

NBP0.0%

Net Margin (TTM)

CHRS-259.4%

NBP0.0%

FCF Margin (TTM)

CHRS-365.2%

NBPN/A

Net Income (TTM)

CHRS$-132M

NBP$-43M

FCF (TTM)

CHRS$-186M

NBP$-55M

EPS (TTM)

CHRS-$0.85

NBP$0.00

ROE (TTM)

CHRS-18336.0%

NBP-2091.0%

ROA (TTM)

CHRS-4290.0%

NBP-1941.0%

ROIC (TTM)

CHRS-10716.0%

NBP-2091.0%

Cash

CHRS$83M

NBP$191M

Debt

CHRS$52M

NBP$0

Net Cash/Debt

CHRS$31M

NBP$191M

Current Ratio (TTM)

CHRS1.77x

NBP7.64x

Quick Ratio (TTM)

CHRS1.58x

NBP7.60x

Debt/Equity (TTM)

CHRS0.85x

NBP0.00x

Debt/Assets (TTM)

CHRS0.0%

NBP0.0%

Interest Coverage (TTM)

CHRSN/A

NBPN/A

Net Debt/EBITDA (TTM)

CHRS0.00x

NBP0.00x

Beta

CHRS0.99

NBP1.69

52W Performance

CHRS-39.2%

NBP-72.5%

YTD Performance

CHRS-21.9%

NBP-67.3%

% from 52W High

CHRS-59.1%

NBP-79.5%

% from 52W Low

CHRS9.9%

NBP6.5%

Asset Turnover (TTM)

CHRS0.17x

NBP0.11x

FCF Yield (TTM)

CHRS-112.7%

NBP-33.9%

Earnings Yield (TTM)

CHRS-80.1%

NBP-26.8%

Dividend Yield (TTM)

CHRSN/A

NBPN/A

Rule of 40

CHRS-429.5

NBP0.0

EV/GP/RG

CHRS0.05

NBPN/A

Ticker research

View CHRS research View NBP research

Metric	CHRS Coherus Oncology Inc	NBP NovaBridge Biosciences
Market & Valuation
Market Cap	$165M	$161M
Enterprise Value	$134M	$-30M
Price	$1.07	$1.40
P/E Ratio	N/A	N/A
P/S Ratio	3.24x	3.29x
EV/Sales	2.63x	0.00x
EV/EBITDA	2.57x	0.00x
P/B Ratio	2.95x	0.77x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.72x	0.55x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	2.04x	N/A
Revenue & Growth
Revenue (TTM)	$51M	$0
Revenue Growth (YoY)	-64.3%	N/A
Forward Rev Growth	67.8%	419.8%
Profitability
Gross Margin (TTM)	68.9%	100.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-288.0%	0.0%
Net Margin (TTM)	-259.4%	0.0%
FCF Margin (TTM)	-365.2%	N/A
Net Income (TTM)	$-132M	$-43M
FCF (TTM)	$-186M	$-55M
EPS (TTM)	-$0.85	$0.00
ROE (TTM)	-18336.0%	-2091.0%
ROA (TTM)	-4290.0%	-1941.0%
ROIC (TTM)	-10716.0%	-2091.0%
Financial Health
Cash	$83M	$191M
Debt	$52M	$0
Net Cash/Debt	$31M	$191M
Current Ratio (TTM)	1.77x	7.64x
Quick Ratio (TTM)	1.58x	7.60x
Debt/Equity (TTM)	0.85x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.99	1.69
52W Performance	-39.2%	-72.5%
YTD Performance	-21.9%	-67.3%
% from 52W High	-59.1%	-79.5%
% from 52W Low	9.9%	6.5%
Efficiency & Yields
Asset Turnover (TTM)	0.17x	0.11x
FCF Yield (TTM)	-112.7%	-33.9%
Earnings Yield (TTM)	-80.1%	-26.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-429.5	0.0
EV/GP/RG	0.05	N/A
Ticker research	View CHRS research	View NBP research

Valuation

P/S Ratio

CHRS

3.24x

NBP

3.29x

EV/FCF

CHRS

-0.72x

NBP

0.55x

Growth & revenue

Revenue Growth TTM

CHRS

-64.3%

Forward Revenue Growth

NBP

419.8%

CHRS

67.8%

Profitability & performance

Gross Margin

NBP

100.0%

CHRS

68.9%

ROE

NBP

-2091.0%

CHRS

-18336.0%

FCF Yield %

NBP

-33.9%

CHRS

-112.7%

52-Week Performance

CHRS

-39.2%

NBP

-72.5%

Detailed metrics comparison

CHRS

Coherus Oncology Inc

NBP

NovaBridge Biosciences

Market Cap

CHRS$165M

NBP$161M

Enterprise Value

CHRS$134M

NBP$-30M

Price

CHRS$1.07

NBP$1.40

P/E Ratio

CHRSN/A

NBPN/A

P/S Ratio

CHRS3.24x

NBP3.29x

EV/Sales

CHRS2.63x

NBP0.00x

EV/EBITDA

CHRS2.57x

NBP0.00x

P/B Ratio

CHRS2.95x

NBP0.77x

P/FCF Ratio

CHRSN/A

NBPN/A

EV/FCF

CHRS-0.72x

NBP0.55x

PEG Ratio

CHRSN/A

NBPN/A

Forward P/E (NTM)

CHRSN/A

NBPN/A

Forward P/S (NTM)

CHRS2.04x

NBPN/A

Revenue (TTM)

CHRS$51M

NBP$0

Revenue Growth (YoY)

CHRS-64.3%

NBPN/A

Forward Rev Growth

CHRS67.8%

NBP419.8%

Gross Margin (TTM)

CHRS68.9%

NBP100.0%

Operating Margin (TTM)

CHRS0.0%

NBP0.0%

EBITDA Margin (TTM)

CHRS-288.0%

NBP0.0%

Net Margin (TTM)

CHRS-259.4%

NBP0.0%

FCF Margin (TTM)

CHRS-365.2%

NBPN/A

Net Income (TTM)

CHRS$-132M

NBP$-43M

FCF (TTM)

CHRS$-186M

NBP$-55M

EPS (TTM)

CHRS-$0.85

NBP$0.00

ROE (TTM)

CHRS-18336.0%

NBP-2091.0%

ROA (TTM)

CHRS-4290.0%

NBP-1941.0%

ROIC (TTM)

CHRS-10716.0%

NBP-2091.0%

Cash

CHRS$83M

NBP$191M

Debt

CHRS$52M

NBP$0

Net Cash/Debt

CHRS$31M

NBP$191M

Current Ratio (TTM)

CHRS1.77x

NBP7.64x

Quick Ratio (TTM)

CHRS1.58x

NBP7.60x

Debt/Equity (TTM)

CHRS0.85x

NBP0.00x

Debt/Assets (TTM)

CHRS0.0%

NBP0.0%

Interest Coverage (TTM)

CHRSN/A

NBPN/A

Net Debt/EBITDA (TTM)

CHRS0.00x

NBP0.00x

Beta

CHRS0.99

NBP1.69

52W Performance

CHRS-39.2%

NBP-72.5%

YTD Performance

CHRS-21.9%

NBP-67.3%

% from 52W High

CHRS-59.1%

NBP-79.5%

% from 52W Low

CHRS9.9%

NBP6.5%

Asset Turnover (TTM)

CHRS0.17x

NBP0.11x

FCF Yield (TTM)

CHRS-112.7%

NBP-33.9%

Earnings Yield (TTM)

CHRS-80.1%

NBP-26.8%

Dividend Yield (TTM)

CHRSN/A

NBPN/A

Rule of 40

CHRS-429.5

NBP0.0

EV/GP/RG

CHRS0.05

NBPN/A

Ticker research

View CHRS research View NBP research

Metric	CHRS Coherus Oncology Inc	NBP NovaBridge Biosciences
Market & Valuation
Market Cap	$165M	$161M
Enterprise Value	$134M	$-30M
Price	$1.07	$1.40
P/E Ratio	N/A	N/A
P/S Ratio	3.24x	3.29x
EV/Sales	2.63x	0.00x
EV/EBITDA	2.57x	0.00x
P/B Ratio	2.95x	0.77x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.72x	0.55x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	2.04x	N/A
Revenue & Growth
Revenue (TTM)	$51M	$0
Revenue Growth (YoY)	-64.3%	N/A
Forward Rev Growth	67.8%	419.8%
Profitability
Gross Margin (TTM)	68.9%	100.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-288.0%	0.0%
Net Margin (TTM)	-259.4%	0.0%
FCF Margin (TTM)	-365.2%	N/A
Net Income (TTM)	$-132M	$-43M
FCF (TTM)	$-186M	$-55M
EPS (TTM)	-$0.85	$0.00
ROE (TTM)	-18336.0%	-2091.0%
ROA (TTM)	-4290.0%	-1941.0%
ROIC (TTM)	-10716.0%	-2091.0%
Financial Health
Cash	$83M	$191M
Debt	$52M	$0
Net Cash/Debt	$31M	$191M
Current Ratio (TTM)	1.77x	7.64x
Quick Ratio (TTM)	1.58x	7.60x
Debt/Equity (TTM)	0.85x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.99	1.69
52W Performance	-39.2%	-72.5%
YTD Performance	-21.9%	-67.3%
% from 52W High	-59.1%	-79.5%
% from 52W Low	9.9%	6.5%
Efficiency & Yields
Asset Turnover (TTM)	0.17x	0.11x
FCF Yield (TTM)	-112.7%	-33.9%
Earnings Yield (TTM)	-80.1%	-26.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-429.5	0.0
EV/GP/RG	0.05	N/A
Ticker research	View CHRS research	View NBP research